<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016522</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00008855</org_study_id>
    <nct_id>NCT01016522</nct_id>
    <nct_alias>NCT01035710</nct_alias>
  </id_info>
  <brief_title>Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Safety and Tolerability of the Ketogenic Diet in ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nutricia North America</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to see if the ketogenic diet (which is high in fat and low in&#xD;
      carbohydrates) is safe and tolerable in amyotrophic lateral sclerosis (ALS) patients who are&#xD;
      fed through a gastrostomy tube. This is not a study to see if ketogenic diets are effective&#xD;
      in the treatment of ALS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study will determine if humans with ALS fed a strictly controlled diet designed to generate large amounts of ketones is safe and well-tolerated without evidence of weight loss or other adverse effect</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate changes in motor function, strength, fatigue, body fat and cognitive function</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>KetoCal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KetoCal tube feeding formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>KetoCal</intervention_name>
    <description>Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates</description>
    <arm_group_label>KetoCal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Familial or sporadic ALS diagnosed as probable, laboratory-supported probable or&#xD;
             definite according to the World Federation of Neurology El Escorial criteria&#xD;
&#xD;
          2. Age 18 or older&#xD;
&#xD;
          3. Capable of providing informed consent and complying with trial procedures&#xD;
&#xD;
          4. Gastrostomy tube in place for the prior month&#xD;
&#xD;
          5. Appel ALS score less than 100&#xD;
&#xD;
          6. Able to stand on a scale with assistance&#xD;
&#xD;
          7. For patients with Appel ALS scores greater than 80, availability of caregiver who is&#xD;
             willing and able to:&#xD;
&#xD;
               -  Prepare, administer and log tube feeds&#xD;
&#xD;
               -  Check and log gastric residuals&#xD;
&#xD;
               -  Assist with weighing subject at home if necessary&#xD;
&#xD;
          8. Willing to chart food intake during the six-month study&#xD;
&#xD;
          9. Patients either not taking Riluzole (Rilutek) or Minocycline or on a stable dose of&#xD;
             these for 30 days&#xD;
&#xD;
         10. Not taking Coenzyme Q10 or on a stable dose and brand for 30 days&#xD;
&#xD;
         11. Absence of exclusion criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Forced vital capacity &lt;50% of predicted&#xD;
&#xD;
          2. Dependence on mechanical ventilation for more than 12 hours per day&#xD;
&#xD;
          3. Exposure to any experimental agent within 30 days of onset of this protocol&#xD;
&#xD;
          4. Women who are pregnant or planning to become pregnant&#xD;
&#xD;
          5. Women of childbearing potential not practicing contraception&#xD;
&#xD;
          6. Enrollment in another research study within 30 days of or during this trial&#xD;
&#xD;
          7. Mini-Mental State Exam (MMSE) score &lt;20&#xD;
&#xD;
          8. Patients with symptomatic cardiac disease or hypercholesterolemia&#xD;
&#xD;
          9. Patients with myocardial infarction within 6 months of this trial&#xD;
&#xD;
         10. Renal dysfunction defined as BUN and creatinine &gt;2XULN&#xD;
&#xD;
         11. Known mitochondrial disease&#xD;
&#xD;
         12. BMI&lt;18.5&#xD;
&#xD;
         13. Prior use of a 4:1 ketogenic diet or Atkins diet within 1 month of this trial&#xD;
&#xD;
         14. Impaired liver function, defined as AST or ALT of 3 X ULN&#xD;
&#xD;
         15. Patients who have a pacemaker or other internal electronic medical device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins ALS Clinic</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>November 18, 2009</study_first_submitted>
  <study_first_submitted_qc>November 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2009</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Vinay Chaudhry</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Ketogenic Diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

